OpGen Group Company Ares Genetics Advances ares-genetics.cloud Platform, Presents Update at Scientific Conferences, Expects Granting of Key Patent
Extended collaboration with leading global generics company Sandoz for optimal antibiotic drug positioning by predictive antibiotic susceptibility testing
Presenting study on combining ares-genetics.cloud with long-read sequencing for rapid antibiotic susceptibility testing in collaboration with
Expects granting of key patent on genetic resistance prediction against antimicrobial drugs
Ares Genetics and Sandoz, the #1 supplier of generic antibiotics globally, have extended their collaboration under a strategic collaboration agreement with the overall goal to develop a digital anti-infectives platform combining established microbiology laboratory methods with advanced bioinformatics and artificial intelligence methods to support drug development and life cycle management. The next phase of the collaboration aims at further leveraging molecular predictive AST and follows the presentation of final results from the initial collaboration phase on optimal positioning of fosfomycin and fosfomycin combination therapies by molecular antibiotic susceptibility testing and in silico modeling at the Antimicrobial Resistance – Genomes, Big Data and Emerging Technologies virtual conference in early November of this year.
Recent advances of Ares Genetics’ ares-genetics.cloud platform enabling accurate and rapid next-generation sequencing (NGS)-based AST using Oxford Nanopore Technology long-read sequencing are scheduled to be presented at the virtual Sequencing, Finishing and Analysis in the Future Meeting, from
Alongside these latest technology development achievements, Ares Genetics has further expanded its intellectual property (IP) portfolio and technology position in data-driven infectious disease diagnostics and recently received communication that the examining division of the
“We’re thrilled about our continued progress in developing and commercializing much needed solutions for rapid predictive antibiotic susceptibility testing using next-generation sequencing as well as the growing demand for our testing-as-a-service and interpretation-as-a-service offerings enabled by patent-pending AI-powered technology,” commented Dr.
For more information, please visit www.opgen.com.
Forward-Looking Statements by
This press release includes statements regarding OpGen’s collaboration with Sandoz and the expected grant of a key patent on genetic resistance prediction. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, including our
FischTank Marketing and PR
Source: OpGen, Inc.